Clinical Trial Update: Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients [NA]

View source ↗

Summary

This clinical trial update reports a triplet regimen of bendamustine, chidamide, and lenalidomide for relapsed and refractory peripheral T-cell lymphoma, which …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Chidamide (chidamide)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Peripheral T-cell Lymphoma | NA | Status: RECRUITING